EDWARDS LIFESCIENCES LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +15.5%

  £171,393,000 → £197,923,000

• Cash

  -15.4%

  £18,521,000 → £15,666,000

• Net assets

  +59.3%

  £22,728,000 → £36,200,000

  highest in 3 filed years

• Employees

  0%

  106 → 106

• Operating profit

  -7%

  £7,178,000 → £6,672,000

• Profit before tax

  +170.8%

  £6,655,000 → £18,020,000

  highest in 3 filed years

• Wages

  +8.2%

  £10,134,000 → £10,963,000

  highest in 3 filed years

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. EDWARDS LIFESCIENCES LIMITED 2000-01-13 → present
2. EDWARDS LIFE SCIENCES LIMITED 2000-01-04 → 2000-01-13
3. INTERCEDE 1510 LIMITED 1999-11-18 → 2000-01-04

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Craufurd Hale Audit Services Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In preparing the financial statements, the directors have considered the ability of the company to continue as a going concern and are actively monitoring the continued impact of Brexit on its financial condition, liquidity, operations and workforce to inform their decisions. The company made a profit before tax for the year ended 31 December 2024 of £18,020,000 (2023: £6,655,000) and at the balance sheet date had net current assets of £35,994,000 (2023: £22,472,000) and net assets of £36,200,000 ( 2023: £22,728,000). The directors have reviewed the latest financial information and prepared cash flow forecasts identifying all known contractual cash commitments for a period including the twelve months from the date of approval of the financial statements and compared this to current cash holdings. The directors have concluded that there are no material uncertainties that lead to significant doubt upon the company's ability to continue as a going concern and therefore the directors believe that it remains appropriate to prepare the financial statements on the going concern basis.”

Significant events

• “On 3 September 2024 the Critical Care and Vascular (CCVAS) was sold to BD (Becton, Dickinson and Company) in an all-cash transaction valued at $4.2 billion and the sales was facilitated at group level. In the UK this will have an impact on assets in this business including workforce reduction.”
• “The Directors expect Edwards Lifesciences Limited to continue focusing on structural heart therapies following the disposal of its Critical Care business unit, completed on 3 September 2024. This strategic shift aligns with the Group's global priorities and strengthens the Company's core operations in the UK and Ireland.”
• “As part of the sale of the Critical Care business unit completed on 3 September 2024, all hospital equipment previously held under fixed assets was disposed of. The disposal formed part of the overall transaction and is reflected within the gain on disposal of the Critical Care business, which resulted in a profit of £10,333,000, as disclosed in Note 10 to the financial statements.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.